| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 90 | 2024 | 1033 | 17.790 |
Why?
|
| Tissue and Organ Procurement | 33 | 2023 | 218 | 10.720 |
Why?
|
| Tissue Donors | 33 | 2024 | 498 | 8.170 |
Why?
|
| Waiting Lists | 29 | 2024 | 220 | 6.910 |
Why?
|
| End Stage Liver Disease | 24 | 2024 | 178 | 5.990 |
Why?
|
| Kidney Transplantation | 15 | 2024 | 621 | 5.430 |
Why?
|
| Graft Survival | 34 | 2023 | 522 | 4.400 |
Why?
|
| Graft Rejection | 15 | 2023 | 576 | 3.740 |
Why?
|
| Transplant Recipients | 11 | 2023 | 210 | 3.140 |
Why?
|
| Organ Transplantation | 10 | 2023 | 163 | 2.920 |
Why?
|
| Heart Transplantation | 9 | 2024 | 853 | 2.790 |
Why?
|
| Retrospective Studies | 79 | 2024 | 15853 | 2.660 |
Why?
|
| Length of Stay | 9 | 2024 | 1272 | 2.660 |
Why?
|
| Liver Neoplasms | 24 | 2024 | 1386 | 2.600 |
Why?
|
| Lung Transplantation | 5 | 2024 | 316 | 2.540 |
Why?
|
| Liver Failure | 6 | 2017 | 92 | 2.420 |
Why?
|
| Allografts | 15 | 2024 | 186 | 2.330 |
Why?
|
| Risk Factors | 45 | 2024 | 9902 | 2.200 |
Why?
|
| Registries | 10 | 2023 | 1367 | 2.120 |
Why?
|
| Donor Selection | 8 | 2021 | 52 | 2.100 |
Why?
|
| Survival Rate | 19 | 2022 | 1997 | 1.830 |
Why?
|
| Carcinoma, Hepatocellular | 17 | 2023 | 957 | 1.810 |
Why?
|
| Humans | 144 | 2024 | 122293 | 1.540 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 267 | 1.340 |
Why?
|
| Adolescent | 40 | 2024 | 18940 | 1.280 |
Why?
|
| Child | 44 | 2024 | 24063 | 1.260 |
Why?
|
| Drug Overdose | 2 | 2020 | 65 | 1.220 |
Why?
|
| Child, Preschool | 32 | 2024 | 13777 | 1.190 |
Why?
|
| Decision Support Techniques | 4 | 2019 | 279 | 1.150 |
Why?
|
| Adult | 52 | 2023 | 28732 | 1.150 |
Why?
|
| Male | 75 | 2024 | 59520 | 1.090 |
Why?
|
| Hepatoblastoma | 4 | 2023 | 214 | 1.070 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 5013 | 1.040 |
Why?
|
| Living Donors | 8 | 2024 | 111 | 1.030 |
Why?
|
| United States | 30 | 2023 | 10487 | 1.020 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2023 | 57 | 1.000 |
Why?
|
| Female | 69 | 2024 | 64882 | 0.990 |
Why?
|
| Postoperative Complications | 12 | 2020 | 2997 | 0.980 |
Why?
|
| Middle Aged | 44 | 2023 | 25639 | 0.980 |
Why?
|
| Infant | 28 | 2024 | 12302 | 0.940 |
Why?
|
| Healthcare Disparities | 4 | 2021 | 410 | 0.940 |
Why?
|
| Age Factors | 8 | 2022 | 2777 | 0.930 |
Why?
|
| Treatment Outcome | 32 | 2022 | 12044 | 0.910 |
Why?
|
| Kidney Failure, Chronic | 6 | 2024 | 861 | 0.900 |
Why?
|
| Severity of Illness Index | 14 | 2024 | 2817 | 0.890 |
Why?
|
| Pancreas Transplantation | 1 | 2023 | 36 | 0.870 |
Why?
|
| Liver | 11 | 2023 | 1851 | 0.860 |
Why?
|
| Transplantation | 2 | 2019 | 29 | 0.840 |
Why?
|
| Databases, Factual | 9 | 2024 | 1158 | 0.830 |
Why?
|
| Biliary Atresia | 2 | 2023 | 201 | 0.810 |
Why?
|
| Health Facilities | 2 | 2019 | 59 | 0.800 |
Why?
|
| Young Adult | 21 | 2022 | 8760 | 0.790 |
Why?
|
| Models, Theoretical | 2 | 2015 | 351 | 0.790 |
Why?
|
| Logistic Models | 7 | 2024 | 1772 | 0.780 |
Why?
|
| Liver Cirrhosis | 10 | 2023 | 825 | 0.770 |
Why?
|
| Prognosis | 15 | 2024 | 4488 | 0.760 |
Why?
|
| Cold Ischemia | 2 | 2018 | 16 | 0.730 |
Why?
|
| Machine Learning | 1 | 2023 | 207 | 0.720 |
Why?
|
| Cystic Fibrosis | 2 | 2020 | 261 | 0.700 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 27 | 0.700 |
Why?
|
| Hospitalization | 3 | 2020 | 1727 | 0.700 |
Why?
|
| ABO Blood-Group System | 3 | 2018 | 65 | 0.690 |
Why?
|
| Learning Curve | 1 | 2020 | 52 | 0.680 |
Why?
|
| Risk Assessment | 9 | 2024 | 3307 | 0.680 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 1008 | 0.660 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2017 | 77 | 0.660 |
Why?
|
| Infant, Newborn | 16 | 2024 | 8096 | 0.660 |
Why?
|
| Proportional Hazards Models | 9 | 2022 | 1298 | 0.650 |
Why?
|
| Alcohol Abstinence | 1 | 2019 | 14 | 0.650 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 40 | 0.640 |
Why?
|
| Liver Diseases | 3 | 2022 | 384 | 0.630 |
Why?
|
| Multivariate Analysis | 8 | 2023 | 1407 | 0.630 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 659 | 0.620 |
Why?
|
| Survival Analysis | 12 | 2021 | 1468 | 0.600 |
Why?
|
| Portal Vein | 3 | 2018 | 92 | 0.600 |
Why?
|
| Critical Care | 3 | 2021 | 647 | 0.600 |
Why?
|
| Suicide | 1 | 2020 | 173 | 0.590 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 30 | 0.560 |
Why?
|
| Narcotics | 1 | 2017 | 62 | 0.560 |
Why?
|
| Blood Loss, Surgical | 2 | 2019 | 140 | 0.560 |
Why?
|
| Alcoholism | 1 | 2019 | 229 | 0.540 |
Why?
|
| Aged | 22 | 2023 | 18784 | 0.540 |
Why?
|
| Malnutrition | 1 | 2019 | 196 | 0.530 |
Why?
|
| Quality Improvement | 1 | 2021 | 620 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 1118 | 0.520 |
Why?
|
| Kidney | 6 | 2023 | 1340 | 0.510 |
Why?
|
| Patient Selection | 6 | 2020 | 685 | 0.500 |
Why?
|
| Reoperation | 3 | 2018 | 807 | 0.490 |
Why?
|
| Models, Statistical | 1 | 2017 | 447 | 0.490 |
Why?
|
| Time Factors | 10 | 2024 | 6182 | 0.490 |
Why?
|
| Endpoint Determination | 1 | 2015 | 52 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 710 | 0.480 |
Why?
|
| Cause of Death | 4 | 2019 | 451 | 0.470 |
Why?
|
| Medical Futility | 1 | 2014 | 36 | 0.460 |
Why?
|
| Neoadjuvant Therapy | 4 | 2020 | 326 | 0.450 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2023 | 643 | 0.450 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 845 | 0.440 |
Why?
|
| Hepatectomy | 1 | 2013 | 122 | 0.400 |
Why?
|
| Heart Failure | 3 | 2020 | 2125 | 0.390 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 99 | 0.390 |
Why?
|
| Altruism | 2 | 2010 | 26 | 0.380 |
Why?
|
| Cohort Studies | 6 | 2022 | 4643 | 0.370 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 110 | 0.370 |
Why?
|
| Blood Transfusion | 1 | 2013 | 303 | 0.370 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 54 | 0.360 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 581 | 0.350 |
Why?
|
| Vascular Grafting | 3 | 2019 | 44 | 0.340 |
Why?
|
| Perioperative Care | 3 | 2021 | 195 | 0.340 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2022 | 387 | 0.340 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2021 | 63 | 0.330 |
Why?
|
| Ablation Techniques | 2 | 2020 | 32 | 0.330 |
Why?
|
| Hepatitis C | 2 | 2023 | 368 | 0.320 |
Why?
|
| Hepatitis C, Chronic | 2 | 2023 | 319 | 0.320 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2008 | 18 | 0.300 |
Why?
|
| Lithotripsy | 1 | 2008 | 22 | 0.300 |
Why?
|
| Pyelonephritis | 1 | 2008 | 26 | 0.300 |
Why?
|
| Embolism, Air | 1 | 2008 | 25 | 0.300 |
Why?
|
| Gift Giving | 1 | 2008 | 18 | 0.300 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2020 | 223 | 0.290 |
Why?
|
| Death | 2 | 2020 | 71 | 0.280 |
Why?
|
| Geography | 2 | 2018 | 112 | 0.270 |
Why?
|
| Erythrocyte Transfusion | 3 | 2019 | 122 | 0.270 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2013 | 31 | 0.260 |
Why?
|
| Immunosuppressive Agents | 5 | 2021 | 645 | 0.260 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 2080 | 0.250 |
Why?
|
| Odds Ratio | 2 | 2021 | 1234 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 872 | 0.220 |
Why?
|
| Sodium | 3 | 2021 | 290 | 0.220 |
Why?
|
| Health Care Rationing | 2 | 2021 | 58 | 0.220 |
Why?
|
| Acute Disease | 2 | 2016 | 1090 | 0.220 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 102 | 0.210 |
Why?
|
| Histocompatibility Testing | 1 | 2023 | 147 | 0.210 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 336 | 0.210 |
Why?
|
| Postoperative Period | 2 | 2020 | 330 | 0.200 |
Why?
|
| Hemochromatosis | 1 | 2022 | 33 | 0.200 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 26 | 0.200 |
Why?
|
| HLA Antigens | 1 | 2023 | 240 | 0.200 |
Why?
|
| Stroke Volume | 1 | 2024 | 446 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2023 | 265 | 0.200 |
Why?
|
| Iliac Vein | 2 | 2019 | 34 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 480 | 0.190 |
Why?
|
| United Kingdom | 2 | 2019 | 189 | 0.190 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 41 | 0.190 |
Why?
|
| Fatty Liver | 2 | 2013 | 182 | 0.190 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2023 | 64 | 0.190 |
Why?
|
| Transplants | 1 | 2021 | 36 | 0.190 |
Why?
|
| Hypernatremia | 1 | 2021 | 27 | 0.190 |
Why?
|
| Coinfection | 1 | 2023 | 170 | 0.190 |
Why?
|
| Aftercare | 2 | 2019 | 145 | 0.190 |
Why?
|
| Protective Factors | 1 | 2021 | 82 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 452 | 0.180 |
Why?
|
| Hyponatremia | 1 | 2021 | 70 | 0.180 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 500 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2023 | 360 | 0.180 |
Why?
|
| Thrombosis | 2 | 2022 | 515 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 140 | 0.170 |
Why?
|
| Epidemics | 1 | 2020 | 52 | 0.170 |
Why?
|
| Chickenpox Vaccine | 1 | 2019 | 13 | 0.170 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 13 | 0.170 |
Why?
|
| Operative Time | 3 | 2019 | 158 | 0.160 |
Why?
|
| Rituximab | 1 | 2020 | 157 | 0.160 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2019 | 42 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2021 | 189 | 0.160 |
Why?
|
| Linear Models | 3 | 2018 | 657 | 0.160 |
Why?
|
| ROC Curve | 1 | 2021 | 552 | 0.160 |
Why?
|
| Hepatic Artery | 1 | 2019 | 52 | 0.160 |
Why?
|
| Pandemics | 3 | 2023 | 1102 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2019 | 39 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 193 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 176 | 0.160 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1247 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 100 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2021 | 217 | 0.160 |
Why?
|
| Iliac Artery | 1 | 2019 | 92 | 0.150 |
Why?
|
| Celiac Artery | 1 | 2018 | 28 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 300 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 121 | 0.150 |
Why?
|
| Incidence | 5 | 2019 | 3018 | 0.150 |
Why?
|
| Hypertension, Portal | 1 | 2018 | 80 | 0.150 |
Why?
|
| Cystatin C | 1 | 2018 | 49 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 85 | 0.140 |
Why?
|
| Ectodermal Dysplasia | 1 | 2017 | 43 | 0.140 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 8 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 239 | 0.140 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 47 | 0.140 |
Why?
|
| Drowning | 1 | 2017 | 32 | 0.140 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 54 | 0.140 |
Why?
|
| Emergencies | 1 | 2018 | 175 | 0.140 |
Why?
|
| Everolimus | 1 | 2017 | 46 | 0.140 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 28 | 0.140 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 174 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 606 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.140 |
Why?
|
| Critical Illness | 2 | 2021 | 588 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2010 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2023 | 841 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2019 | 487 | 0.130 |
Why?
|
| Hospitals | 1 | 2018 | 397 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2017 | 261 | 0.130 |
Why?
|
| Craniosynostoses | 1 | 2017 | 131 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 232 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1750 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3301 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2796 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 294 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 220 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 360 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Lung | 1 | 2022 | 1476 | 0.120 |
Why?
|
| Metabolomics | 1 | 2017 | 389 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 744 | 0.120 |
Why?
|
| California | 1 | 2014 | 127 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6290 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2017 | 475 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1424 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2013 | 13 | 0.110 |
Why?
|
| Warm Ischemia | 1 | 2013 | 15 | 0.110 |
Why?
|
| Pathology, Surgical | 1 | 2013 | 20 | 0.110 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 38 | 0.110 |
Why?
|
| Pancreatitis, Chronic | 1 | 2013 | 68 | 0.110 |
Why?
|
| Pancreatectomy | 1 | 2013 | 135 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2017 | 477 | 0.100 |
Why?
|
| Abdomen | 1 | 2013 | 128 | 0.100 |
Why?
|
| Bilirubin | 1 | 2013 | 126 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2016 | 525 | 0.100 |
Why?
|
| Robotics | 1 | 2013 | 109 | 0.100 |
Why?
|
| Hepacivirus | 2 | 2023 | 242 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 182 | 0.090 |
Why?
|
| HIV Infections | 1 | 2023 | 1858 | 0.090 |
Why?
|
| Sarcoma | 1 | 2013 | 197 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2012 | 112 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1004 | 0.090 |
Why?
|
| Policy | 2 | 2023 | 34 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2016 | 1463 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 98 | 0.090 |
Why?
|
| Disease Progression | 3 | 2022 | 1990 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1022 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2020 | 231 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2014 | 995 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 139 | 0.080 |
Why?
|
| Anastomosis, Surgical | 2 | 2019 | 169 | 0.080 |
Why?
|
| Clinical Protocols | 2 | 2020 | 237 | 0.080 |
Why?
|
| New York City | 1 | 2008 | 58 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2023 | 736 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2009 | 403 | 0.070 |
Why?
|
| Neutrophils | 1 | 2009 | 371 | 0.070 |
Why?
|
| Program Development | 1 | 2008 | 189 | 0.070 |
Why?
|
| Diverticulum | 1 | 2005 | 28 | 0.060 |
Why?
|
| Duodenal Diseases | 1 | 2005 | 34 | 0.060 |
Why?
|
| Biopsy | 2 | 2021 | 1246 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2023 | 36 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 923 | 0.050 |
Why?
|
| Ascites | 1 | 2023 | 88 | 0.050 |
Why?
|
| Perfusion | 1 | 2023 | 196 | 0.050 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 75 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 237 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 5963 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1147 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 162 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 179 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 23 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 815 | 0.050 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 23 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 86 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 297 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 147 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 155 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2020 | 47 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 54 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 273 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 208 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 239 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 285 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 119 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 35 | 0.040 |
Why?
|
| Transplantation, Heterotopic | 1 | 2019 | 32 | 0.040 |
Why?
|
| Anatomic Variation | 1 | 2019 | 2 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 792 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1413 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 102 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 63 | 0.040 |
Why?
|
| Neutropenia | 1 | 2020 | 202 | 0.040 |
Why?
|
| Biomarkers | 2 | 2018 | 2933 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 104 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 221 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2030 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 230 | 0.040 |
Why?
|
| Texas | 2 | 2018 | 3528 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 1490 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 214 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 200 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 783 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 758 | 0.040 |
Why?
|
| Brain Death | 1 | 2018 | 55 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 755 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 208 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 182 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2018 | 356 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1227 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 126 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3229 | 0.030 |
Why?
|
| Creatinine | 1 | 2018 | 379 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 140 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 533 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1131 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1677 | 0.030 |
Why?
|
| Sirolimus | 1 | 2017 | 220 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2826 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 963 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 371 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1238 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 300 | 0.030 |
Why?
|
| Los Angeles | 1 | 2012 | 18 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2013 | 140 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 115 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 116 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 297 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2016 | 776 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 266 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2010 | 46 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2009 | 15 | 0.020 |
Why?
|
| Portal System | 1 | 2009 | 33 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 71 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1140 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 30 | 0.020 |
Why?
|
| Veterans | 1 | 2021 | 1710 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1568 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1250 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 202 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 68 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 246 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2009 | 173 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 235 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 209 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2010 | 255 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2010 | 184 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5734 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1213 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2005 | 16 | 0.020 |
Why?
|
| Pancreatic Ducts | 1 | 2005 | 23 | 0.020 |
Why?
|
| C-Peptide | 1 | 2006 | 108 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 1103 | 0.020 |
Why?
|
| North America | 1 | 2006 | 234 | 0.020 |
Why?
|
| Canada | 1 | 2006 | 294 | 0.020 |
Why?
|
| Duodenum | 1 | 2005 | 100 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 1191 | 0.010 |
Why?
|
| Pancreas | 1 | 2005 | 214 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3657 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 33721 | 0.000 |
Why?
|